Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma.

ABSTRACT:

Introduction

Melphalan, as a bifunctional alkylating agent has been shown to be selectively efficient in BRCA-deficient case reports of epithelial ovarian cancer (EOC). The clinical benefit of melphalan on unselected platinum-resistant EOC population and stratified by BRCA status has not been clearly elucidated. We aimed to determine the response to melphalan in patients with recurrent EOC after platinum-based therapy.

Material and methods

This retrospective observational study included patients with recurrent EOC treated with melphalan between February 2007 to July 2020. Eligibility criteria included having a histological confirmation of EOC, previous treatment with carboplatin plus paclitaxel regimens, and disease recurrence during treatment with or within 6 months of the

SUBMITTER: Conteduca V 

PROVIDER: S-EPMC8336462 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature